Market Overview:
The global coronary intervention drug eluting stent market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cardiovascular diseases, technological advancements in stent technology, and rising demand for minimally invasive procedures. Based on type, the global coronary intervention drug eluting stent market is segmented into below 40 µm, 40 µm- 65 µm, and above 65 µm segments. The below 40 µm segment is expected to account for the largest share of the global coronary intervention drug eluting stent market in 2018 owing to its low cost and easy availability. However, this segment is projected to witness a decline in its share by 2030 due to increasing adoption of advanced technologies such as bioresorbable vascular scaffolds (BVSs). Based on application, the global coronary intervention drug eluting stent market is divided into hospital-based applications and clinic-based applications segments. The hospital-based applications segment accounted for majority share of the overall coronary intervention drug eluting stent market in 2017 and it is anticipated that this trend would continue during forecast period as well.
Product Definition:
A coronary intervention drug eluting stent is a medical device that is inserted into the coronary arteries to prop them open and improve blood flow to the heart muscle. The importance of a coronary intervention drug eluting stent is that it can help prevent heart attacks and improve patient outcomes.
Below 40 µm:
Below 40 micro meters is the thickness of an average human hair. It is also known as nanometer which means one-billionth of a meter. The size and structure of stent are determined by its intended use in medical procedures. A stent used for angioplasty or coronary intervention has different dimensions and surface area than one used for peripheral vascular disease or renal disease, etc.
40 µm- 65 µm:
40 µm-65 µm is a range of stent sizes that are used in coronary intervention. The 40-65 um stent size segment is commonly used for the treatment of Coronary Artery Disease (CAD) and it's being considered as one of the most effective treatments for reducing heart attack risk, owing to its ability to reduce blood cholesterol levels and prevent reoccurrence.
Application Insights:
Based on application, the global coronary intervention drug eluting stent market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a high prevalence of patients suffering from acute coronary syndrome (ACS) requiring immediate medical attention. Moreover, increasing number of hospitals offering cardiac care units across the globe is expected to boost demand for CVD treatment options such as drug-eluting stents over the forecast period.
The other applications include primary healthcare settings and secondary/ tertiary healthcare settings.
Regional Analysis:
North America dominated the global coronary intervention drug eluting stent market in 2016 with a revenue share of over 40%. This is attributed to the presence of well-established healthcare infrastructure, high adoption rate for advanced technologies, and availability of reimbursement facilities. Moreover, increasing prevalence of heart diseases owing to sedentary lifestyle and consumption of junk food is propelling the demand for CVIS procedures in this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to factors such as improving healthcare infrastructure and economic development coupled with rising patient awareness levels regarding various treatment options offered by coronary stenting devices manufacturers. Furthermore, government initiatives are being undertaken in order to reduce cardiovascular disease (CVD) rates through control over modifiable risk factors such as smoking cessation & alcohol consumption along with improved dietary habits among others. These initiatives are anticipated favorably impact industry growth prospects during the forecast period in this region as well as others mentioned above below).
Growth Factors:
- Increasing incidence of coronary artery diseases (CAD) due to changing lifestyle and dietary habits.
- Growing geriatric population susceptible to CAD.
- Technological advancements in the field of coronary intervention drug eluting stents (CIEDS).
- Rising healthcare expenditure and increasing awareness about treatment options for CAD patients among people in developing countries.
Scope Of The Report
Report Attributes
Report Details
Report Title
Coronary Intervention Drug Eluting Stent Market Research Report
By Type
Below 40 µm, 40 µm- 65 µm, Above 65 µm
By Application
Hospital, Clinic, Others
By Companies
Synlas GmbH, YILSON, BrosMed Medical, SCITECH Medical, Wellinq, Degania Silicone, Alvimedica, Interventional Medical Device Solutions, Comed BV, iVascular, LEPU Medical, Eurocor Tech GmbH, OrbusNeich, Endocor GmbH, Meril Life Sciences, Acrostak, Boston Scientific Corporation, B. Braun, Biotronik, Abbott, MicroPort Medical Group, Philips, Terumo Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Coronary Intervention Drug Eluting Stent Market Report Segments:
The global Coronary Intervention Drug Eluting Stent market is segmented on the basis of:
Types
Below 40 µm, 40 µm- 65 µm, Above 65 µm
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Synlas GmbH
- YILSON
- BrosMed Medical
- SCITECH Medical
- Wellinq
- Degania Silicone
- Alvimedica
- Interventional Medical Device Solutions
- Comed BV
- iVascular
- LEPU Medical
- Eurocor Tech GmbH
- OrbusNeich
- Endocor GmbH
- Meril Life Sciences
- Acrostak
- Boston Scientific Corporation
- B. Braun
- Biotronik
- Abbott
- MicroPort Medical Group
- Philips
- Terumo Corporation
Highlights of The Coronary Intervention Drug Eluting Stent Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Below 40 µm
- 40 µm- 65 µm
- Above 65 µm
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Coronary Intervention Drug Eluting Stent Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A coronary intervention drug eluting stent is a type of medical device that helps to prevent blood clots from forming in the arteries that supply blood to the heart.
Some of the major players in the coronary intervention drug eluting stent market are Synlas GmbH, YILSON, BrosMed Medical, SCITECH Medical, Wellinq, Degania Silicone, Alvimedica, Interventional Medical Device Solutions, Comed BV, iVascular, LEPU Medical, Eurocor Tech GmbH, OrbusNeich, Endocor GmbH, Meril Life Sciences, Acrostak, Boston Scientific Corporation, B. Braun, Biotronik, Abbott, MicroPort Medical Group, Philips, Terumo Corporation.
The coronary intervention drug eluting stent market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Coronary Intervention Drug Eluting Stent Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Coronary Intervention Drug Eluting Stent Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Coronary Intervention Drug Eluting Stent Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Coronary Intervention Drug Eluting Stent Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Coronary Intervention Drug Eluting Stent Market Size & Forecast, 2018-2028
4.5.1 Coronary Intervention Drug Eluting Stent Market Size and Y-o-Y Growth
4.5.2 Coronary Intervention Drug Eluting Stent Market Absolute $ Opportunity
Chapter 5 Global Coronary Intervention Drug Eluting Stent Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Coronary Intervention Drug Eluting Stent Market Size Forecast by Type
5.2.1 Below 40 µm
5.2.2 40 µm- 65 µm
5.2.3 Above 65 µm
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Coronary Intervention Drug Eluting Stent Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Coronary Intervention Drug Eluting Stent Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Coronary Intervention Drug Eluting Stent Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Coronary Intervention Drug Eluting Stent Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Coronary Intervention Drug Eluting Stent Analysis and Forecast
9.1 Introduction
9.2 North America Coronary Intervention Drug Eluting Stent Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Coronary Intervention Drug Eluting Stent Market Size Forecast by Type
9.6.1 Below 40 µm
9.6.2 40 µm- 65 µm
9.6.3 Above 65 µm
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Coronary Intervention Drug Eluting Stent Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Coronary Intervention Drug Eluting Stent Analysis and Forecast
10.1 Introduction
10.2 Europe Coronary Intervention Drug Eluting Stent Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Coronary Intervention Drug Eluting Stent Market Size Forecast by Type
10.6.1 Below 40 µm
10.6.2 40 µm- 65 µm
10.6.3 Above 65 µm
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Coronary Intervention Drug Eluting Stent Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Coronary Intervention Drug Eluting Stent Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Coronary Intervention Drug Eluting Stent Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Coronary Intervention Drug Eluting Stent Market Size Forecast by Type
11.6.1 Below 40 µm
11.6.2 40 µm- 65 µm
11.6.3 Above 65 µm
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Coronary Intervention Drug Eluting Stent Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Coronary Intervention Drug Eluting Stent Analysis and Forecast
12.1 Introduction
12.2 Latin America Coronary Intervention Drug Eluting Stent Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Coronary Intervention Drug Eluting Stent Market Size Forecast by Type
12.6.1 Below 40 µm
12.6.2 40 µm- 65 µm
12.6.3 Above 65 µm
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Coronary Intervention Drug Eluting Stent Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Coronary Intervention Drug Eluting Stent Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Coronary Intervention Drug Eluting Stent Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Coronary Intervention Drug Eluting Stent Market Size Forecast by Type
13.6.1 Below 40 µm
13.6.2 40 µm- 65 µm
13.6.3 Above 65 µm
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Coronary Intervention Drug Eluting Stent Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Coronary Intervention Drug Eluting Stent Market: Competitive Dashboard
14.2 Global Coronary Intervention Drug Eluting Stent Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Synlas GmbH
14.3.2 YILSON
14.3.3 BrosMed Medical
14.3.4 SCITECH Medical
14.3.5 Wellinq
14.3.6 Degania Silicone
14.3.7 Alvimedica
14.3.8 Interventional Medical Device Solutions
14.3.9 Comed BV
14.3.10 iVascular
14.3.11 LEPU Medical
14.3.12 Eurocor Tech GmbH
14.3.13 OrbusNeich
14.3.14 Endocor GmbH
14.3.15 Meril Life Sciences
14.3.16 Acrostak
14.3.17 Boston Scientific Corporation
14.3.18 B. Braun
14.3.19 Biotronik
14.3.20 Abbott
14.3.21 MicroPort Medical Group
14.3.22 Philips
14.3.23 Terumo Corporation
